A database of FDA approved therapeutic peptides and proteins
Details of Th1217 which contains 1 entries. |
Entry 1 | |
(1) Primary information | |
---|---|
ID | 1827 |
ThPP ID | Th1217 |
Therapeutic Peptide/Protein Name | Anti-inhibitor coagulant complex |
Sequence | NA view full sequnce in fasta |
Functional Classification | Ia |
Molecular Weight | NA |
Chemical Formula | NA |
Isoelectric Point | NA |
Hydrophobicity | NA |
Melting Point (℃) | NA |
Half Life | 4-7 hours |
Description | Anti-inhibitor coagulant complex is a freeze-dried sterile human plasma fraction with factor VIII inhibitor bypassing activity to be reconstituted for intravenous administration. Anti-inhibitor coagulant complex contains mainly non-activated factors II, IX, and X and mainly activated factor VII. It is manufactured from large pools of human plasma. |
Indication/Disease | Controlling bleeding episodes or bleeding during surgery in patients who have hemophilia A or B with inhibitors. |
Pharmacodynamics | Multiple interactions of the components in anti-inhibitor coagulant complex restore the impaired thrombin generation of hemophilia patients with inhibitors. In vitro, anti-inhibitor coagulant complex shortens the activated partial thromboplastin time of plasma containing factor VIII inhibitor. |
Mechanism of Action | NA |
Toxicity | NA |
Metabolism | NA |
Absorption | NA |
Volume of Distribution | NA |
Clearance | NA |
Categories | Blood Coagulation Factors, Antihemophilic Agent |
Patents Number | NA |
Date of Issue | NA |
Date of Expiry | NA |
Drug Interaction | Antifibrinolytic Agents: May enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex (Human). Avoid combination |
Target | NA |
Information of corresponding available drug in the market | |
Brand Name | Feiba Nf |
Company | NA |
Brand Discription | Feiba NF is a clotting factor. It works by correcting the clotting defect, which allows blood clots to form. |
Prescribed for | Controlling bleeding episodes or bleeding during surgery in patients who have hemophilia A or B with inhibitors. It should not be used to treat patients with other bleeding disorders. |
Chemical Name | NA |
Formulation | NA |
Physcial Appearance | Solid |
Route of Administration | Intravenous |
Recommended Dosage | 50-100 units/kg per dose (maximum: 100 units/kg [single dose], 200 units/kg/day [total daily dose]). Dosage and duration of treatment depend on the location and extent of bleeding and clinical condition of the patient. |
Contraindication | Known anaphylactic or severe hypersensitivity to anti-inhibitor coagulant complex or any component of the formulation, including factors of the kinin generating system; disseminated intravascular coagulation (DIC); acute thrombosis or embolism (including myocardial infarction) |
Side Effects | chest pain or discomfort |
Useful Link | http://www.feiba.com/us/forms/feiba_nf_pi.pdf , https://www.drugs.com/cdi/anti-inhibitor-coagulant-complex.html |
PubMed ID | 6777002 |
3-D Structure | N.A. |